睿知中国疾病研究地图
候选清单0

正在招募肝细胞癌不分期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

GPC3-directed CAR-T in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma

ClinicalTrials.gov 上登记的一项肝细胞癌开放试验,由上海交通大学医学院附属仁济医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方上海交通大学医学院附属仁济医院Renji Hospital上海医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT05926726,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 8

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(8 项)收起清单
  1. 18 岁 至 75 岁;性别:不限

    登记记录的入选字段

  2. Histologically-confirmed hepatocellular carcinoma (HCC)

    入选标准第 5 条

  3. Barcelona Clinic Liver Cancer (BCLC) stage C or B and Child-Pugh ≤7

    入选标准第 11 条

    Another primary malignancy within 3 years (with some exceptions for completely-resected early-stage tumors)

    排除标准第 4 条

  4. Non-hematological AEs induced by previous treatment must have recovered to CTCAE ≤1, except for alopecia and peripheral neuropathy

    入选标准第 15 条

  5. Eastern Cooperative Oncology Group (ECOG) performance status scale ≤1

    入选标准第 4 条

  6. Per RECIST v1.1, at least one measurable lesion

    入选标准第 9 条

  7. Active HCV, HIV, or syphilis

    排除标准第 7 条

  8. Women of childbearing potential must agree to use an effective and reliable contraceptive method during 28 days prior to lymphodepletion to 1 year post infusion; Male patients who have not undergone vasectomy and have sexual activity with women of childbearing potential must agree to the use of a barrier contraceptive method since lymphodepletion to 1year post infusion, and sperm donation is prohibited during the study

    入选标准第 16 条

    Pregnant or lactating women

    排除标准第 15 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:化验:血常规、肝肾功能。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT05926726,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. 18-75 years-old, male or female
  2. Voluntarily willing to participate in the study and sign the written informed consent form
  3. Life expectation ≥12 weeks
  4. Eastern Cooperative Oncology Group (ECOG) performance status scale ≤1
  5. Histologically-confirmed hepatocellular carcinoma (HCC)
  6. No benefits from curative surgery or other local therapies are expected at screening, judged by investigators
  7. Radiologically-confirmed progression disease after at least one prior line of systematic treatment and limited benefits from current guideline or consensus for hepatocellular carcinoma are expected at screening, judged by investigators
  8. Fresh samples or FFPE, immunohistochemistry (IHC)-stained GPC-3 positive with intensity ++ or +++
  9. Per RECIST v1.1, at least one measurable lesion
  10. Manageable lung metastasis
  11. Barcelona Clinic Liver Cancer (BCLC) stage C or B and Child-Pugh ≤7
  12. No active HBV infections
  13. Adequate organ functions
  14. Adequate venous access for APH
  15. Non-hematological AEs induced by previous treatment must have recovered to CTCAE ≤1, except for alopecia and peripheral neuropathy
  16. Women of childbearing potential must agree to use an effective and reliable contraceptive method during 28 days prior to lymphodepletion to 1 year post infusion; Male patients who have not undergone vasectomy and have sexual activity with women of childbearing potential must agree to the use of a barrier contraceptive method since lymphodepletion to 1year post infusion, and sperm donation is prohibited during the study
  17. Women of childbearing potential must have negative serum β-hCG test result at screening and 48 hours prior to lymphodepletion

排除标准:Exclusion Criteria:

  1. Cholangiocarcinoma or histological-mixed hepatocellular cholangiocarcinoma
  2. Active brain metastasis
  3. Primary lesion or infused lesions with the longest diameter ≥15cm, or other potential risk which might not be appropriate for further study treatment judged by the investigator
  4. Another primary malignancy within 3 years (with some exceptions for completely-resected early-stage tumors)
  5. Systematic autoimmune disorders requiring long-term systematic immunosuppression
  6. Previously treated with any genetically engineered modified T cell therapy (TCR-T/CAR-T) or other CGT
  7. Active HCV, HIV, or syphilis
  8. History of organ transplant
  9. Uncontrolled or active infection at screening, prior to APH, 72 hours prior to lymphodepletion or 5 days prior to JWATM214 infusion
  10. With severe cardiovascular disease
  11. History or presence of clinically-relevant CNS disorders
  12. Current presence of hepatic encephalopathy
  13. ≥G2 hemorrhage within 30 days prior to screening, or in need of long-term anticoagulants
  14. Active digestive ulcer or gastrointestinal bleeding within 3 months prior to screening
  15. Pregnant or lactating women
  16. Not satisfying wash-out period for APH
  17. Unable or unwilling to comply with the study protocol, judged by the investigator
  18. Other situations implying that the subject might not be appropriate to participate in the study
  19. Previously allergic or intolerable to JWATM214 or its components

引自 ClinicalTrials.gov, NCT05926726, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT05926726,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT05926726